90 related articles for article (PubMed ID: 38612604)
1. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.
Fukagawa S; Miyata K; Yotsumoto F; Kiyoshima C; Nam SO; Anan H; Katsuda T; Miyahara D; Murata M; Yagi H; Shirota K; Yasunaga S; Kato K; Miyamoto S
Cancer Sci; 2017 May; 108(5):886-896. PubMed ID: 28231414
[TBL] [Abstract][Full Text] [Related]
3. A Comparative Analysis of Naïve Exosomes and Enhanced Exosomes with a Focus on the Treatment Potential in Ovarian Disorders.
Mousaei Ghasroldasht M; Liakath Ali F; Park HS; Hadizadeh M; Weng SHS; Huff A; Vafaei S; Al-Hendy A
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793064
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype.
Lenherr SM; Tsai S; Silva Neto B; Sullivan TB; Cimmino CB; Logvinenko T; Gee J; Huang W; Libertino JA; Summerhayes IC; Rieger-Christ KM
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28218662
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-RIBOTAC Strategy Enabling Tumor-Specific Targeted Degradation of MicroRNA for Precise Cancer Therapy.
Fang Y; Wu Q; Wang F; Liu Y; Zhang H; Yang C; Zhu Z
Small Methods; 2024 May; ():e2400349. PubMed ID: 38794853
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
8. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
9. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2.
Song Z; Liao C; Yao L; Xu X; Shen X; Tian S; Wang S; Xing F
Cancer Gene Ther; 2023 Apr; 30(4):596-607. PubMed ID: 36494581
[TBL] [Abstract][Full Text] [Related]
10. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
11. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
12. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN/AKT and SOCS6/STAT3 pathways.
Sun L; Ke M; Yin M; Zeng Y; Ji Y; Hu Y; Fu S; Zhang C
Cancer Sci; 2024 Jan; 115(1):155-169. PubMed ID: 37972389
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.
Sameti P; Tohidast M; Amini M; Bahojb Mahdavi SZ; Najafi S; Mokhtarzadeh A
Cancer Cell Int; 2023 Jul; 23(1):134. PubMed ID: 37438760
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
